Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) serve as the standard of care for the first-line treatment of patients with lung cancers with <i>EGFR</i>-activating mutations. However, the acquisition of resistance to EGFR TKIs is almost inevitable, with extreme...

Full description

Bibliographic Details
Main Authors: Kenichi Suda, Tetsuya Mitsudomi
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cells
Subjects:
non-small cell lung cancer
drug-tolerant cells (DTCs)
drug-tolerant persisters (DTPs)
bypass pathway
acquired resistance
EGFR tyrosine kinase inhibitors (EGFR TKIs)
Online Access:https://www.mdpi.com/2073-4409/10/7/1590

Internet

https://www.mdpi.com/2073-4409/10/7/1590

Similar Items